This site is intended for health professionals only

Friday 20 September 2019
Share |

Topic: Rheumatology

September 13, 2019
This article reviews the epidemiology, pathogenesis, investigation and management of prosthetic joint infections in patients with rheumatoid arthritis
Infection following prosthetic joint infection (PJI) is a recognised surgical complication. However, it has serious consequences requiring both surgical and antimicrobial management. Patients with rheumatoid arthritis (RA) are both more likely to have joint replacement due to abnormal anatomy and be immunosuppressed due to the underlying disease and immunomodulatory therapies. These factors make them more at risk as a population for post- operative infection.  


September 13, 2019
This review aims to highlight and address the challenges in presentation, investigation and management of septic arthritis and vertebral osteomyelitis in adults treated with biologic therapies
September 9, 2019
The antigen-specific liposome immunotherapy treatment helps restore immune cells to healthy function
People living with inflammatory autoimmune disease could benefit from an 'immune system reboot', and researchers have isolated specific cells to target.
The University of Queensland's Professor Ranjeny Thomas said the research findings give hope for similar new immunotherapies for people with diseases like rheumatoid arthritis and vasculitis.
"People with these diseases currently require daily medications to modify or suppress their immune system," she said.
August 15, 2019
First time that researchers have been able to use synovial fluid from human osteoarthritis patients to excite sensory nerve cells
A team at the University of Cambridge has shown how, in osteoarthritis patients, the viscous lubricant that ordinarily allows our joints to move smoothly triggers a pain response from nerve cells similar that caused by chilli peppers.
August 8, 2019
Urine biomarkers represent promising candidates for the early diagnosis as well as the monitoring of disease activity and therapeutic responses in lupus nephritis
University of Houston researcher Chandra Mohan is reporting in Arthritis Research and Therapy that clotting proteins, both those that promote blood clots (pro-thrombotic) and those that work to dissipate them (thrombolytic), are elevated in the urine of patients who suffer from lupus nephritis (LN).
July 18, 2019
New research on the autoimmune disease systemic lupus erythematosus (SLE) provides hints to the origins of this disorder and the results have been published in Nature Immunology
In people with SLE, their B cells are abnormally activated. That makes them produce antibodies that react against their own tissues, causing a variety of symptoms, such as fatigue, joint pain, skin rashes and kidney problems.
July 18, 2019
The development of high-throughput ‘omics’ technologies (genomics, transcriptomics or metabolomics) that allow simultaneous examination of thousands of genes, transcripts and proteins is expected to change the playing field
Despite the large number of laboratory tests ordered daily, diagnostic tools proven to be effective when managing immune-mediated diseases are limited, often forcing physicians to rely on a mixture of clinical, laboratory and radiological features to establish a diagnosis. 
July 15, 2019
The rapid, non-invasive technique could help clinicians diagnose the disease earlier, and assess how effectively the selected treatment is controlling the progression of the disease
A new way of detecting rheumatoid arthritis using infrared light could offer an objective way of diagnosing the disease and monitoring treatment effectiveness, a University of Birmingham, UK study shows.
June 20, 2019
The purpose of the study was to assess the drug’s pharmacokinetics, efficacy and safety for treatment of MAS and to confirm the proposed dose regimen
SOBI has announced that new research demonstrating the effects of emapalumab in patients with macrophage activation syndrome (MAS), a form of secondary haemophagocytic lymphohistiocytosis (HLH) complicating systemic juvenile idiopathic arthritis (sJIA), was presented at the EULAR/Paediatric Rheumatology European Society (PReS) Scientific Congress in Madrid.  
June 19, 2019
Research led by the University of Birmingham in the UK has found re-purposing already existing drugs or combining therapies could be used to treat patients who have difficult to treat autoimmune diseases
Funded by Versus Arthitis, research led by the University of Birmingham's Institute of Inflammation and Ageing and Institute of Cardiovascular Sciences has been published in Proceedings of the National Academy of Sciences.1
The research, a collaboration with the University of Oxford, University of Cambridge, University of York, Université Rennes in France, and the University of Lausanne in Switzerland, was supported by the National Institute for Health Research Birmingham Biomedical Research Centre.
June 16, 2019
Study also reveals venous thromboembolism and epilepsy as potential novel comorbidities
A study has shown increased rates of type I diabetes and inflammatory bowel disease (IBD) in patients that go on to develop rheumatoid arthritis (RA).1 
Results of the study demonstrate that the RA group reported significantly more cases of inflammatory bowel disease (1.9% vs. 0.5%, p<0.001) and type I diabetes (1.3% vs. 0.4%, p=0.01) versus controls.1
June 15, 2019
Initial pilot data support the use of new neurostimulation treatment in a larger study in patients who have failed current standard of care
The results of a study suggest that electro stimulation of the vagus nerve could provide a novel treatment approach for patients with rheumatoid arthritis.1 
This is a really exciting development. For many patients suffering from rheumatoid arthritis, current treatments don’t work, or aren’t tolerated,” said Professor Thomas Dörner, Chairperson of the Scientific Programme Committee, EULAR. 
June 14, 2019
In the European Union alone, an extra one million employees could be in work each day if early interventions were more widely accessible for people with rheumatic and musculoskeletal diseases (RMDs)
EULAR has launched the Time2Work campaign to raise awareness of the impact rheumatic and musculoskeletal diseases (RMDs) have, not only on individuals, but wider society, productivity and our economies and what can be done to improve this situation.
Affecting one quarter of the EU population (120 million), RMDs are the biggest cause of sick leave and premature retirement due to physical disability. As one of the main causes of physical disability, RMDs contribute considerably to loss of productivity in the workplace.
June 14, 2019
Over half of patients and rheumatologists report diagnosis within six weeks as the most problematic standard of care
The results of a large pan-European survey presented at EULAR 2019 investigated significant gaps in rheumatoid arthritis care across 16 patient-centred Standards of Care (SoC) in rheumatoid arthritis.1  
June 14, 2019
Huge impact of pain and sleep on mental health raises questions about the level of care offered to patients
A survey has highlighted the significant impact of rheumatic and musculoskeletal diseases (RMDs) on mental health and a worrying lack of psychological care.1
June 13, 2019
Study includes data from over 8000 people with psoriatic arthritis from four Nordic countries
The results of a study presented EULAR 2019 suggest that overall cancer risk is not linked to tumour necrosis factor inhibitor (TNFi) use in psoriatic arthritis.
June 13, 2019
Study reports no vaccine infections in children given live-attenuated booster vaccine while on immune suppressing therapies
A study presented at EULAR 2019, jointly organised with the Paediatric Rheumatology Society (PReS), demonstrate no vaccine infections, and no disease flare, in the 234 rheumatic patients who received live-attenuated booster vaccination while taking immune suppressing therapies.1
June 6, 2019
Older men with scleroderma have more oestrogen than postmenopausal women with the disease, which could explain why the disease is often more severe in men
Oestrogen is the quintessentially female hormone.
It is surprising, then, that a Medical University of South Carolina (MUSC) study found that a type of oestrogen, oestradiol, was more abundant in older men with scleroderma than in postmenopausal women with the disease. The MUSC team reports the findings of their National Institutes of Health (NIH)-funded study in Arthritis Research & Therapy.
June 3, 2019
The management and treatment of rheumatoid arthritis is becoming more individualised thanks to the combined efforts of basic scientists and clinicians
The ultimate goal of modern medicine is a personalised approach for the individual patient, that is, a tailored management based on a finely tuned definition of immunogenetics, epigenetics, microbiome, and biomarkers, to maximise results and minimise risks of treatment (particularly of new biologics and small molecules). 
June 2, 2019
The evidence-based recommendations for the prevention and management of adult antiphospholipid syndrome are designed to help guide practice – and improve quality of care and patient outcomes
EULAR has published a set of recommendations for the management of antiphospholipid syndrome in adults.
Based on evidence from a systematic literature review and expert opinion, overarching principles and recommendations were formulated and voted. Three overarching principles and twelve recommendations were formulated. The overarching principles are:
May 31, 2019
A Federation called Sjögren Europe has been created by the national patient associations of ten European countries
Sjögren Europe is a European Federation of national patient associations for Sjögren’s Syndrome and rheumatic diseases created in February 2019 by the patient organisations of Finland, France, Greece, Italy, Netherlands, Portugal, Spain, Switzerland, United Kingdom and the support of the informal association of Belgium.
May 30, 2019
The research was supported by Wellcome Trust, Versus Arthritis, and NIHR Birmingham Biomedical Research Centre, which is based at University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham in the UK
Pioneering research by scientists at the Universities of Oxford and Birmingham published in Nature brings us a step closer to developing targeted therapies for inflammatory diseases.1
The research team shows, for the first time, that different types of fibroblasts - the most common cells of connective tissue in animals - are organised in different layers in the joint and are responsible for two very different forms of arthritis; osteoarthritis and rheumatoid arthritis.
May 30, 2019
Scientists used powerful cryo-electron microscopes at the University of Leeds' Astbury Centre to reveal the structure of the regulator, comprised of two proteins in the body called BRISC and SHMT2, to understand for the first time how they work together in a cell.
Scientists have identified a new internal regulator that helps control the body's response to fight infection.
The discovery could be a target for new drugs to tackle autoimmune diseases, such as lupus and scleroderma, where healthy tissues are attacked by the body's own immune system.
"We want to put a brake on the body's own immune system to stop it turning on itself," said Dr Elton Zeqiraj from the University of Leeds.